Atherosclerotic Cardiovascular Disease Market to Observe Impressive Growth During the Forecast Period (2023-2032), Evaluates DelveInsight | Amgen, Novo Nordisk A/S, Ionis Pharmaceuticals, NewAmsterdam Pharma, ResverlogixCorp, Novartis

DelveInsights Atherosclerotic Cardiovascular Disease (ASCVD) Market Insights, Epidemiology, and Market Forecast-2032 report offers an in-depth understanding of the Atherosclerotic Cardiovascular Disease, historical and forecasted epidemiology as well as the Atherosclerotic Cardiovascular Disease market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Atherosclerotic Cardiovascular Disease market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Atherosclerotic Cardiovascular Disease Market Forecast

Some of the key facts of the Atherosclerotic Cardiovascular Disease Market Report:

• The Atherosclerotic Cardiovascular Disease market size was valued approximately USD 23 billion in 2022 and is anticipated to grow with a significant CAGR during the study period (2019-2032)
• As of 2022, there were 55,455,209 diagnosed cases of Atherosclerotic Cardiovascular Disease (ASCVD) in the 7MM; it is anticipated that this figure will increase at a significant CAGR from 2019 to 2032
• There are numerous medications in the Atherosclerotic Cardiovascular Disease (ASCVD) pipeline at the moment. The most prominent medications for this indication include Olpasiran, TQJ230 (pelacarsen), Ziltivekimab, and a few more
• With 26,043,092 cases, the total number of diagnosed prevalent cases of atherosclerotic cardiovascular disease (ASCVD) in the US accounted for the highest number of cases among the 7MM, and it is anticipated that this number would rise sharply in the near future due to advancements in diagnostic testing and population growth
• With 5,742,367 cases, Germany had the highest diagnosed prevalent population of atherosclerotic cardiovascular disease (ASCVD) among the European nations in 2022, followed by France with 4,351,010. However, with 3,192,649 cases in the same year, Spain had the lowest diagnosed prevalence rate among the 7MM
• In 2022, Japan was home to 8,228,510 instances of Atherosclerotic Cardiovascular Disease (ASCVD), with an expected increase through the end of 2032
• Key Atherosclerotic Cardiovascular Disease Companies: Amgen, Novo Nordisk A/S, Ionis Pharmaceuticals, NewAmsterdam Pharma, ResverlogixCorp, LIB Therapeutics, Novartis, Merck Sharp & Dohme LLC, Novartis Pharmaceuticals, BioMarin Pharmaceutical, AstraZeneca, Zhejiang Genfleet Therapeutics Co., Ltd., and others
• Key Atherosclerotic Cardiovascular Disease Therapies: Olpasiran, Ziltivekimab, Olezarsen, Obicetrapib(TA-8995), Apabetalone, LIB003 (Lerodalcibep), CSL112: CSL Behring, TQJ230 (pelacarsen), MK-0616, Inclisiran, Ertugliflozin, Tetrahydrobiopterin, MEDI6570, GFH312, and others
• The Atherosclerotic Cardiovascular Disease epidemiology based on gender analyzed that men bear a greater burden than women regarding Atherosclerotic Cardiovascular Disease (ASCVD) in the 7MM
• The Atherosclerotic Cardiovascular Disease market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Atherosclerotic Cardiovascular Disease pipeline products will significantly revolutionize the Atherosclerotic Cardiovascular Disease market dynamics.

Atherosclerotic Cardiovascular Disease Overview

As a result of plaque buildup, atherosclerotic cardiovascular disease (ASCVD) causes arteries to constrict, limiting healthy blood flow to organs and the arms and legs. As a result, the blood supply to the heart or brain becomes stopped, which can cause heart attacks and strokes.

Get a Free sample for the Atherosclerotic Cardiovascular Disease Market Report

https://www.delveinsight.com/report-store/atherosclerotic-cardiovascular-disease-ascvd-market

Atherosclerotic Cardiovascular Disease Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Atherosclerotic Cardiovascular Disease Epidemiology Segmentation:

The Atherosclerotic Cardiovascular Disease market report proffers epidemiological analysis for the study period 20192032 in the 7MM segmented into:

• Total Prevalence of Atherosclerotic Cardiovascular Disease
• Prevalent Cases of Atherosclerotic Cardiovascular Disease by severity
• Gender-specific Prevalence of Atherosclerotic Cardiovascular Disease
• Diagnosed Cases of Episodic and Chronic Atherosclerotic Cardiovascular Disease

Download the report to understand which factors are driving Atherosclerotic Cardiovascular Disease epidemiology trends @ Atherosclerotic Cardiovascular Disease Epidemiology Forecast

Atherosclerotic Cardiovascular Disease Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Atherosclerotic Cardiovascular Disease market or expected to get launched during the study period. The analysis covers Atherosclerotic Cardiovascular Disease market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Atherosclerotic Cardiovascular Disease Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Atherosclerotic Cardiovascular Disease Therapies and Key Companies

• Olpasiran: Amgen
• Ziltivekimab: Novo Nordisk A/S
• Olezarsen: Ionis Pharmaceuticals
• Obicetrapib(TA-8995): NewAmsterdam Pharma
• Apabetalone: ResverlogixCorp
• LIB003 (Lerodalcibep): LIB Therapeutics
• CSL112: CSL Behring
• TQJ230 (pelacarsen): Novartis Pharmaceuticals
• MK-0616: Merck Sharp & Dohme LLC
• Inclisiran: Novartis Pharmaceuticals
• Ertugliflozin: Merck Sharp & Dohme LLC
• Tetrahydrobiopterin: BioMarin Pharmaceutical
• MEDI6570: AstraZeneca
• GFH312: Zhejiang Genfleet Therapeutics Co., Ltd.

Discover more about therapies set to grab major Atherosclerotic Cardiovascular Disease market share @ Atherosclerotic Cardiovascular Disease Treatment Market

Atherosclerotic Cardiovascular Disease Market Strengths

• Robust pipeline of drugs targeting a variety of different and more effective pathogenic mechanisms in Atherosclerotic Cardiovascular Disease (ASCVD).

Atherosclerotic Cardiovascular Disease Market Opportunities

• The lack of FDA-approved treatments for lowering Lp(a)presents an exciting opportunity for focused research on developing precise therapies in the realm of ASCVD

Scope of the Atherosclerotic Cardiovascular Disease Market Report

• Study Period: 20192032
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Atherosclerotic Cardiovascular Disease Companies: Amgen, Novo Nordisk A/S, Ionis Pharmaceuticals, NewAmsterdam Pharma, ResverlogixCorp, LIB Therapeutics, Novartis, Merck Sharp & Dohme LLC, Novartis Pharmaceuticals, BioMarin Pharmaceutical, AstraZeneca, Zhejiang Genfleet Therapeutics Co., Ltd., and others
• Key Atherosclerotic Cardiovascular Disease Therapies: Olpasiran, Ziltivekimab, Olezarsen, Obicetrapib(TA-8995), Apabetalone, LIB003 (Lerodalcibep), CSL112: CSL Behring, TQJ230 (pelacarsen), MK-0616, Inclisiran, Ertugliflozin, Tetrahydrobiopterin, MEDI6570, GFH312, and others
• Atherosclerotic Cardiovascular Disease Therapeutic Assessment: Atherosclerotic Cardiovascular Disease current marketed and Atherosclerotic Cardiovascular Disease emerging therapies
• Atherosclerotic Cardiovascular Disease Market Dynamics: Atherosclerotic Cardiovascular Disease market drivers and Atherosclerotic Cardiovascular Disease market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porters five forces, BCG Matrix, Market entry strategies
• Atherosclerotic Cardiovascular Disease Unmet Needs, KOLs views, Analysts views, Atherosclerotic Cardiovascular Disease Market Access and Reimbursement

To know more about Atherosclerotic Cardiovascular Disease companies working in the treatment market, visit @ Atherosclerotic Cardiovascular Disease Clinical Trials and Therapeutic Assessment

Table of Contents

1. Atherosclerotic Cardiovascular Disease Market Report Introduction

2. Executive Summary for Atherosclerotic Cardiovascular Disease

3. SWOT analysis of Atherosclerotic Cardiovascular Disease

4. Atherosclerotic Cardiovascular Disease Patient Share (%) Overview at a Glance

5. Atherosclerotic Cardiovascular Disease Market Overview at a Glance

6. Atherosclerotic Cardiovascular Disease Disease Background and Overview

7. Atherosclerotic Cardiovascular Disease Epidemiology and Patient Population

8. Country-Specific Patient Population of Atherosclerotic Cardiovascular Disease

9. Atherosclerotic Cardiovascular Disease Current Treatment and Medical Practices

10. Atherosclerotic Cardiovascular Disease Unmet Needs

11. Atherosclerotic Cardiovascular Disease Emerging Therapies

12. Atherosclerotic Cardiovascular Disease Market Outlook

13. Country-Wise Atherosclerotic Cardiovascular Disease Market Analysis (20192032)

14. Atherosclerotic Cardiovascular Disease Market Access and Reimbursement of Therapies

15. Atherosclerotic Cardiovascular Disease Market Drivers

16. Atherosclerotic Cardiovascular Disease Market Barriers

17. Atherosclerotic Cardiovascular Disease Appendix

18. Atherosclerotic Cardiovascular Disease Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

Latest Reports by DelveInsight

Fungal Pneumonia Market

DelveInsight’s “Fungal Pneumonia Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the Fungal Pneumonia, historical and forecasted epidemiology as well as the Fungal Pneumonia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Gene Therapy Market

Gene Therapy Market By Vector Type (Viral And Non-Viral), By Delivery Type (Ex Vivo And In Vivo), By Indication (Neurological, Oncological, Hematological, Ophthalmological, And Others), by geography is expected to grow at a steady CAGR forecast till 2028 owing to the rising therapeutic value of gene therapy and surge in research and development activities for gene therapy.

H1n1 Influenza Market

DelveInsight’s “H1N1 (Swine Influenza) Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the H1N1 (Swine Influenza), historical and forecasted epidemiology as well as the H1N1 (Swine Influenza) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Hypothyroidism Market

DelveInsight’s “Hypothyroidism Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the Hypothyroidism, historical and forecasted epidemiology as well as the Hypothyroidism market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Lyme Disease Market

DelveInsight’s “Lyme Disease Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the Lyme Disease, historical and forecasted epidemiology as well as the Lyme Disease market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Gingivitis Market

DelveInsight’s “Gingivitis Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the Gingivitis, historical and forecasted epidemiology as well as the Gingivitis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Other Reports Offered By DelveInsight

Blood Glucose Monitoring Systems Market | Chronic Rhinosinusitis Phenotype With Nasal | Polyps Market | Breast Pumps Market | Pars Planitis Market | Patient Monitoring Devices Market | Typhoid Market | Zika Virus Market | Opioid Use Disorder Market | Fungal Pneumonia Market | Gene Therapy Market | H1n1 Influenza Market | Hypothyroidism Market | Lyme Disease Market | Gingivitis Market | Marfan Syndrome Market | Morquio Syndrome Market | Pyoderma Gangrenosum Market | Yellow Fever Market | Coronary Guidewires Market | Dental Equipment Market | Diabetic Ketoacidosis Market | Duodenoscope Market | Erythromelalgia Market | Fatty Acid Oxidation Disorders Market | Germ Cell Tumor Market | Oropharyngeal Cancer Market | Positive Air Pressure Device Market | Total Artificial Heart Market

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

COMTEX_440513151/2582/2023-09-19T08:27:47